Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac (CVAC) Research & Development (2019 - 2025)

Historic Research & Development for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to -$44.7 million.

  • CureVac's Research & Development rose 1852.3% to -$44.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.2 million, marking a year-over-year increase of 6518.66%. This contributed to the annual value of $163.5 million for FY2024, which is 3133.78% up from last year.
  • Per CureVac's latest filing, its Research & Development stood at -$44.7 million for Q3 2025, which was up 1852.3% from -$39.5 million recorded in Q2 2025.
  • In the past 5 years, CureVac's Research & Development ranged from a high of $1.3 billion in Q4 2021 and a low of -$158.1 million during Q2 2021
  • Over the past 5 years, CureVac's median Research & Development value was -$30.2 million (recorded in 2024), while the average stood at $60.0 million.
  • The largest annual percentage gain for CureVac's Research & Development in the last 5 years was 45538.18% (2021), contrasted with its biggest fall of 14142756.64% (2021).
  • Over the past 5 years, CureVac's Research & Development (Quarter) stood at $1.3 billion in 2021, then tumbled by 92.1% to $99.5 million in 2022, then surged by 114.29% to $213.1 million in 2023, then surged by 31.33% to $279.9 million in 2024, then plummeted by 115.98% to -$44.7 million in 2025.
  • Its Research & Development was -$44.7 million in Q3 2025, compared to -$39.5 million in Q2 2025 and -$39.5 million in Q1 2025.